Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABRA1 | P14867 | 3/20 | 0.46 |
| ▸ | GABRB2 | P47870 | 2/20 | 0.46 |
| ▸ | TSHR | P16473 | 2/20 | 0.42 |
| ▸ | LMNA | P02545 | 2/20 | 0.42 |
| ▸ | GABRG2 | P18507 | 2/20 | 0.42 |
| ▸ | GABRB3 | P28472 | 2/20 | 0.42 |
| ▸ | FAAH | O00519 | 2/20 | 0.42 |
| ▸ | CA1 | P00915 | 1/20 | 0.42 |
| ▸ | CA2 | P00918 | 1/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.42 |
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
| ▸ | GABRB1 | P18505 | 1/20 | 0.42 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.42 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.42 |
| ▸ | HTR2C | P28335 | 1/20 | 0.42 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.42 |
| ▸ | GABRA3 | P34903 | 1/20 | 0.42 |
| ▸ | HTR2B | P41595 | 1/20 | 0.42 |
| ▸ | GABRA2 | P47869 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL2866667 | 0.98 | GABRA1 (0.44) | GABRA1GABRB2TSHRLMNAGABRG2 | |
| SCHEMBL5431002 | 0.85 | GABRA1 (0.46) | GABRA1GABRB2TSHRLMNAGABRG2 | |
| SCHEMBL3893551 | 0.85 | MAPT (0.41) | GABRA1GABRB2TSHRLMNAGABRG2 | |
| SCHEMBL3955367 | 0.82 | ALDH1A1 (0.44) | GABRA1GABRB2TSHRLMNAGABRG2 | |
| SCHEMBL657406 | 0.82 | MAPT (0.43) | GABRA1GABRB2TSHRLMNACA1 | |
| SCHEMBL30125097 | 0.82 | MAPT (0.43) | GABRA1GABRB2TSHRLMNACA1 | |
| SCHEMBL31495901 | 0.81 | GABRA1 (0.43) | GABRA1GABRB2TSHRLMNAGABRG2 | |
| SCHEMBL10926304 | 0.81 | MAPT (0.43) | GABRA1GABRB2TSHRLMNAGABRG2 | |
| SCHEMBL14016878 | 0.81 | GABRA1 (0.43) | GABRA1GABRB2TSHRLMNAGABRG2 | |
| SCHEMBL3727784 | 0.81 | MAPT (0.39) | GABRA1GABRB2TSHRLMNAGABRG2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 155 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116874648-A | Trivalent vanadium complex catalyst containing bidentate ligand and preparation method and application thereof | 合肥工业大学 | 2023-10-13 | — | — | CN | claimed |
| US-12030876-B2 | Aryl hydrocarbon receptor (AHR) agonists and uses thereof | Ikena Oncology, Inc. (US) | 2024-07-09 | — | — | US | disclosed |
| US-12030876-B2 | Aryl hydrocarbon receptor (AHR) agonists and uses thereof | Ikena Oncology, Inc. (US) | 2024-07-09 | — | — | US | disclosed |
| US-20240224783-A1 | ORGANIC ELECTROLUMINESCENT MATERIALS AND DEVICES | UNIVERSAL DISPLAY CORPORATION (US) | 2024-07-04 | — | — | US | disclosed |
| US-20240074301-A1 | ORGANIC ELECTROLUMINESCENT MATERIALS AND DEVICES | UNIVERSAL DISPLAY CORPORATION (US) | 2024-02-29 | — | — | US | disclosed |
| US-20240074301-A1 | ORGANIC ELECTROLUMINESCENT MATERIALS AND DEVICES | UNIVERSAL DISPLAY CORPORATION (US) | 2024-02-29 | — | — | US | disclosed |
| US-20240025918-A1 | KRAS G12D Inhibitors | JACOBIO PHARMACEUTICALS CO., LTD. (CN) | 2024-01-25 | — | — | US | disclosed |
| US-20230371358-A1 | ORGANIC ELECTROLUMINESCENT MATERIALS AND DEVICES | UNIVERSAL DISPLAY CORPORATION (US) | 2023-11-16 | — | — | US | disclosed |
| US-20230371358-A1 | ORGANIC ELECTROLUMINESCENT MATERIALS AND DEVICES | UNIVERSAL DISPLAY CORPORATION (US) | 2023-11-16 | — | — | US | disclosed |
| US-20230348510-A1 | ORGANIC ELECTROLUMINESCENT MATERIALS AND DEVICES | UNIVERSAL DISPLAY CORPORATION (US) | 2023-11-02 | — | — | US | disclosed |
| EP-1717298-A1 | LUBRICATING OIL ADDITIVE AND LUBRICATING OIL COMPOSITION CONTAINING SAME | Adeka Corporation (JP) | 2006-11-02 | — | — | EP | disclosed |
| EP-0942006-B1 | Catalyst for olefin polymer production and process for olefin polymer production employing the catalyst | TOSOH CORP (JP) | 2003-06-04 | — | — | EP | disclosed |
| EP-0849292-B1 | Olefin polymerisation catalysts and processes for producing olefin polymers | TOSOH CORP (JP) | 2002-08-21 | — | — | EP | disclosed |
| US-6372681-B1 | METALLOCENE OF TRANSITION METAL AND; METAL OXIDE, SULFIDE, PHOSPHIDE, CARBIDE, NITRIDE, AND/OR SELENIDE; ORGANOALKALINE EARTH OR ZINC COMPOUND; AND ORGANOALUMINUM COMPOUND | TOSOH CORPORATION (JP) | 2002-04-16 | — | — | US | disclosed |
| US-6337297-B1 | CHROMIUM CATALYST FOR TRIMERIZATION OF ETHYLENE WITH MULTIDENTATE LIGAND OR HALOGEN, CARBOXY GROUP | TOSOH CORPORATION (JP) | 2002-01-08 | — | — | US | disclosed |
| US-6197990-B1 | REACTING CYCLOPENTADIENE AND METAL HYDRIDE IN PRESENCE OF AMINE COMPOUND | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2001-03-06 | — | — | US | disclosed |
| US-6110858-A | AN OLEFIN POLYMERIZATION CATALYST CONSISTS OF A TRANSITION METAL COMPOUND, A MODIFIED CLAY COMPOUND CONTAINING CLAY MINERAL AND AN AMINE COMPOUND AND AN ORGANOALUMINUM COMPOUND | TOSOH CORPORATION (JP) | 2000-08-29 | — | — | US | disclosed |
| EP-0963990-A1 | PROCESS FOR PRODUCING CYCLOPENTADIENYL METAL SALTS AND PROCESS FOR PRODUCING CYCLOPENTADIENE DERIVATIVES BY UTILIZING THE SAME | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 1999-12-15 | — | — | EP | disclosed |
| EP-0942006-A2 | Catalyst for olefin polymer production and process for olefin polymer production employing the catalyst | TOSOH CORPORATION (JP) | 1999-09-15 | — | — | EP | disclosed |
| EP-0849292-A1 | Olefin polymerisation catalysts and processes for producing olefin polymers | TOSOH CORPORATION (JP) | 1998-06-24 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12030876-B2 | Aryl hydrocarbon receptor (AHR) agonists and uses thereof | AHR, ARNT, HCAR1 | GABRA1 713/4885GABRB2 1001/4885TSHR 156/4885 |
| US-20240074301-A1 | ORGANIC ELECTROLUMINESCENT MATERIALS AND DEVICES | ICOSLG, OCIAD2, OSBP | GABRA1 3198/4885GABRB2 2734/4885TSHR 1042/4885 |
| US-20240224783-A1 | ORGANIC ELECTROLUMINESCENT MATERIALS AND DEVICES | OCIAD2, OCIAD1, ICOSLG | GABRA1 1816/4885GABRB2 1639/4885TSHR 2736/4885 |
| US-20230348510-A1 | ORGANIC ELECTROLUMINESCENT MATERIALS AND DEVICES | LBR, OXER1, OXSR1 | GABRA1 1422/4885GABRB2 1638/4885TSHR 312/4885 |
| US-20230371358-A1 | ORGANIC ELECTROLUMINESCENT MATERIALS AND DEVICES | LIFR, SOD1, ROS1 | GABRA1 1432/4885GABRB2 1679/4885TSHR 189/4885 |
| US-20240025918-A1 | KRAS G12D Inhibitors | KRAS, NRAS, HRAS | GABRA1 3975/4885GABRB2 4007/4885TSHR 4206/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.